Workflow
Should Investors Buy Intuitive Machines Stock Right Now in 2025?
The Motley Fool· 2025-01-09 13:00
Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...
Crescent Capital: Share Price Finally Catching Up To Fundamentals
Seeking Alpha· 2025-01-09 13:00
I recently co-authored: My Top 10 BDCs for 2025 here on Seeking Alpha. While the list focused on their quality in lieu of their valuations, there were some BDCs I considered quality that I had to leave off theContributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due dilige ...
Should You Forget Palantir and Buy These 3 Artificial Intelligence (AI) Stocks Right Now?
The Motley Fool· 2025-01-09 13:00
Palantir Technologies (PLTR -2.52%) was one of the hottest artificial intelligence (AI) stocks in 2024, and for good reason. Growth accelerated as U.S. commercial clients began adopting the company's Artificial Intelligence Platform while its largest customer, the U.S. government, also began to increase spending.The company still has a lot of opportunity in front of it, as much of its early AI success with commercial clients has come from proof-of-concept work. As it moves these customers to production, rev ...
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
GlobeNewswire· 2025-01-09 13:00
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced that Boehringer Ingelheim has exercised an option for rights to a fourth novel oncology target from an ongoing discovery collaboration. The target was discovered using OBTs proprietary OGAP® splice variant discovery platform and the option exercise triggers a milestone payment to OBT. Immuno ...
NEWSMAX HOSTS EXCLUSIVE INAUGURATION EVE CELEBRATION AT THE ANDREW W. MELLON AUDITORIUM
GlobeNewswire· 2025-01-09 13:00
Washington, DC, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The stage is set for an unforgettable evening as Newsmax presents the premier Inauguration Eve event of the weekend. Hosted by Chris Ruddy, CEO of Newsmax, this prestigious gathering will bring together the nation’s most influential leaders and honored guests to celebrate President Donald J. Trump's second inauguration. The evening will welcome Members of Congress, newly appointed Administration officials, prominent business leaders, and those closest to the ...
agentOS Proptech Group Joins Volaris Group to Support Long-Term Growth in Property Management Vertical
GlobeNewswire· 2025-01-09 13:00
TORONTO and CARDIFF, United Kingdom, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Volaris Group, a global leader in acquiring and growing vertical market technology companies, today announced the acquisition of agentOS Proptech Group, a leading provider of property management software solutions across the UK. This acquisition extends Volaris Group’s commitment to supporting long-term growth in property management technology. agentOS Proptech Group, creator of products agentOS, agentPay and Calmony, has built a reputat ...
Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential
GlobeNewswire· 2025-01-09 13:00
FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies, FMC-220 demonstrated unprecedented potency and durable anti-tumor activity in vitro and in vivo at low doses. IND anticipated in 2H 2025Frontier’s pipeline of precision medicines continues to progress rapidly, with interim clinical data for FMC-376, an ON+OFF KRASG12C inhibitor currently in the Phase 1/2 PROSPER trial, expected 2H 2025 BOSTON an ...
BCA: Advanced Technologies for Restoring Trust and Reclaiming Lost Assets
GlobeNewswire· 2025-01-09 13:00
New York, NY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The rapid evolution of blockchain and advanced computational technologies has sparked a significant transformation in digital asset recovery services. Leading the initiative, Broker Complaint Alert, together with industry leaders such as Chiron Investigations and Hawthorn Cyber Security, are pioneering the use of sophisticated computational solutions to enhance the efficiency and effectiveness of their recovery operations. The integration of cutting-edge com ...
Nyrstar NV – Postponed assessment of request for appointment of provisional administrator
GlobeNewswire· 2025-01-09 13:00
Regulated Information – inside information Nyrstar NV – Postponed assessment of request for appointment of provisional administrator 9 January 2025 at 14.00 CET As previously disclosed, a group of shareholders filed a petition for interim measures on 11 March 2024 in the framework of the proceedings on the merits pending before the Antwerp Commercial Court, Turnhout division, against Nyrstar NV, certain current and former directors, certain Trafigura companies and Deloitte (see also link). By judgment of 9 ...
Vortex Announces Private Placement of C$400,000 of Unsecured Convertible Debentures
GlobeNewswire· 2025-01-09 13:00
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) ("Vortex” or the "Company") is pleased to announce that it intends to complete a non-brokered private placement of unsecured convertible debentures of the Company (the “Convertible Debentures”) in an aggregate amount of C$400,000 (the “Offering”). The Convertible Debentures will be sold in pri ...